对抗平行β片形成的一种非共价方法.
Huaqiang Zeng1, Xiaowu Yang, Robert A Flowers
1Department of Chemistry, Natural Sciences Complex, State University of New York, Buffalo, New York 14260, USA.
Journal of the American Chemical Society
|March 21, 2002
概括
研究人员使用链和DNA模板创建了稳定的混合双重体. 这些结构形成β片,防止聚合,并与单个组件相比显示增强的稳定性.
科学领域:
- 超分子化学 超分子化学
- 生物物理化学 生物物理化学
- 结构生物学 结构生物学
背景情况:
- 的自我组装对于生物结构至关重要.
- 设计稳定的-DNA复合体仍然是一个挑战.
- 了解分子相互作用指导着新生物材料的开发.
研究的目的:
- 为了研究-DNA杂交双重体的形成和稳定性.
- 探索将三链连接到DNA模板的结构后果.
- 描述具有和没有DNA支架的的自我组装行为.
主要方法:
- 合成四个三链和一个互补的DNA复合体.
- 通过将质与DNA结合而形成混合双重体.
- 使用1D和2D核磁共振 (NMR) 光谱学进行结构性表征.
- 通过异热定位热量计 (ITC) 进行热力学分析.
主要成果:
- 四个不同的杂交双重组 (1a.2a,1a.2b,1b.2a,1b.2b) 在与相同的DNA末端连接时形成,具有双链β片段.
- 核磁共振证实了扩展的形状,通过键和侧链相互作用稳定.
- 该DNA模板抑制了进一步的聚.
- 对不同DNA末端的附着导致未定义的构造,而单独的则显示随机关联.
- ITC发现混合双重1a.2a在热力学上比单独的DNA模板或更稳定.
结论:
- 链可以形成具有DNA模板的稳定,富含β片的混合复合体.
- DNA双重体作为支架,指导组装并防止聚合.
- 混合双车表现出增强的稳定性,为设计新型自组装系统提供了潜力.
相关概念视频
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:26Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...